


Actionable Strategies in Community Oncology to Achieve Equity in Triple-negative Breast Cancer



Bibliography and Suggested Reading

- Adamson BJS, Cohen AB, Estevez M, et al. Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment. *J Clin Oncol*. 2019;37(18_suppl):LBA1.
- Ambroggi F, Fornili M, Boracchi P, et al. Trop-2 is a determinant of breast cancer survival [published correction appears in: *PLoS One*. 2014;9(10):e110606]. *PLoS One*. 2014;9(5):e96993.
- American Cancer Society. Breast cancer facts and figures. ACS website. <https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.html>. Accessed June 2023.
- Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. *N Engl J Med*. 2021;384(16):1529–1541.
- Bardia A, Krop I, Merci-Bernstam F, et al. Datopotamab deruxtecan (dato-DXd) in advanced triple-negative breast cancer (TNBC): updated results from the phase 1 TROPION-PanTumor01 study. Abstract P6-10-03. Presented at: San Antonio Breast Cancer Symposium; December 6–10, 2022; San Antonio, Texas.
- Bardia A, Tolaney SM, Loirat D, et al. Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): final results from the phase 3 ASCENT study. Abstract 1071. Presented at: 2022 ASCO Annual Meeting; June 3, 2022; Chicago, Illinois.
- Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nat Rev Clin Oncol*. 2016;13(11):674–690.
- Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. *Bioconjug Chem*. 2015;26(5):919–931.
- Carey LA, Loirat D, Punie K, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. *NPJ Breast Cancer*. 2022;8(1):72.
- Carey LA, Zelnak A, Rugo HS, et al. Assessment of sacituzumab govitecan in black patients from the phase 3 ASCENT study in metastatic triple-negative breast cancer. Poster P05-16-07. Presented at: San Antonio Breast Cancer Symposium; December 7–10, 2021; San Antonio, Texas.
- Chen Y, Susick L, Davis M, et al. Evaluation of triple-negative breast cancer early detection via mammography screening and outcomes in African American and white American patients [published correction appears in *JAMA Surg*. 2020;155(5):455]. *JAMA Surg*. 2020;155(5):440–442.
- Cho B, Han Y, Lian M, et al. Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer. *JAMA Oncol*. 2021;7(7):1016–1023.
- Dimarco R, Guinigundo AS, Valdeuzua C. Uncovering and Addressing Implicit Bias in Oncology. *J Adv Pract Oncol*. 2023;14(3):195-199.
- Dietze EC, Chavez TA, Seewaldt VL. Obesity and triple-negative breast cancer: disparities, controversies, and biology. *Am J Pathol*. 2018;188(2):280–290.
- Domchek SM, Yao S, Chen F, et al. Comparison of the prevalence of pathogenic variants in cancer susceptibility genes in black women and non-Hispanic white women with breast cancer in the United States. *JAMA Oncol*. 2021;7(7):1045–1050.
- FDA-approved drug product: sacituzumab govitecan. February 3, 2023. FDA website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s0351bl.pdf. Accessed June 2023.
- FDA-approved drug product: trastuzumab deruxtecan. November 4, 2022. FDA website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s0241bl.pdf. Accessed June 2023.
- Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med*. 2010;363(20):1938–1948.
- Gatti V, Bongiorno-Borbone L, Fierro C, et al. p63 at the crossroads between stemness and metastasis in breast cancer. *Int J Mol Sci*. 2019;20(11):2683.
- Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in: *Oncotarget*. 2020;11(10):942]. *Oncotarget*. 2015;6(26):22496–22512.

- Goldenberg DM, Sharkey RM. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. *Expert Opin Biol Ther.* 2020;20(8):871–885.
- Hamilton EP, Dosunmu O, Shastry M, et al. A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC). *J Clin Oncol.* 2023; 41(16_suppl):1004.
- Hossain F, Danos D, Prakash O, et al. Neighborhood social determinants of triple-negative breast cancer. *Front Public Health.* 2019;7:18.
- Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. *Cancer J.* 2021;27(1):8–16.
- Hurvitz S, Tolaney SM, Punie K, et al. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Abstract GS3-06. Presented at: San Antonio Breast Cancer Symposium Virtual Meeting; December 8–11, 2020; San Antonio, Texas.
- Krop IE, Masuda N, Mukohara T, et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). Abstract 1002. Presented at: 2022 ASCO Annual Meeting; June 3, 2022; Chicago, Illinois.
- Lebert JM, Lester R, Powell E, et al. Advances in the systemic treatment of triple-negative breast cancer. *Curr Oncol.* 2018;25(suppl 1):S142–S150.
- Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. *JAMA Oncol.* 2019;5(10):e191870.
- Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. *N Engl J Med.* 2022;387(1):9–20.
- Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. *Target Oncol.* 2017;12(6):719–739.
- Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. *Ther Adv Med Oncol.* 2020;12:1758835920915980.
- National Cancer Institute. Genetics of breast and gynecologic cancers (PDQ). Updated March 10, 2023. National Cancer Institute website. <https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq>. Accessed June 2023.
- National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer. Version 4.2023; March 23, 2023. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed June 2023.
- Newman LA, Kaljee LM. Health disparities and triple-negative breast cancer in African American women: a review. *JAMA Surg.* 2017;152(5):485–493.
- Patel MI, Lopez AM, Blackstock W, et al. Cancer disparities and health equity: a policy statement from the American Society of Clinical Oncology [published correction appears in *J Clin Oncol.* 2020;38(33):3976]. *J Clin Oncol.* 2020;38(29):3439–3448.
- Penner LA, Dovidio JF, Gonzalez R, et al. The effects of oncologist implicit racial bias in racially discordant oncology interactions. *J Clin Oncol.* 2016;34(24):2874–2880.
- Penner LA, Harper FWK, Dovidio JF, et al. The impact of black cancer patients' race-related beliefs and attitudes on racially-discordant oncology interactions: a field study. *Soc Sci Med.* 2017;191:99–108.
- Prakash O, Hossain F, Danos D, et al. Racial disparities in triple negative breast cancer: a review of the role of biologic and non-biologic factors. *Front Public Health.* 2020;8:576964.
- Rebner M, Pai VR. Breast cancer screening recommendations: African American women are at a disadvantage. *J Breast Imag.* 2020;2(5):416–421.
- Rugo HS, Crossno CL, Gesthalter YB, et al. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2–Expressing Metastatic Breast Cancer. *JCO Oncology Practice.* 2023; 00:1–8.
- Saha P, Nanda R. Concepts and targets in triple-negative breast cancer: recent results and clinical implications. *Ther Adv Med Oncol.* 2016;8(5):351–359.
- Sharma P. Biology and management of patients with triple-negative breast cancer. *Oncologist.* 2016;21(9):1050–1062.
- Siddharth S, Sharma D. Racial disparity and triple-negative breast cancer in African-American women: a multifaceted affair between obesity, biology, and socioeconomic determinants. *Cancers (Basel).* 2018;10(12):514.
- Silber JH, Rosenbaum PR, Ross RN, et al. Disparities in breast cancer survival by socioeconomic status despite Medicare and Medicaid insurance. *Milbank Q.* 2018;96(4):706–754.

- 
- Tarantino P, Morganti S, Curigliano G. Biologic therapy for advanced breast cancer: recent advances and future directions. *Expert Opin Biol Ther.* 2020;20(9):1009–1024.
- Tarantino P, Tolaney SM. Detecting and Managing T-DXd–Related Interstitial Lung Disease: The Five “S” Rules. *JCO Oncology Practice.* 2023; 00:1–2.
- Unger JM, Hershman DL, Osarogiagbon RU, et al. Representativeness of black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies. *JNCI Cancer Spectr.* 2020;4(4):pkaa034.
- Unger JM, Hershman DL, Till C, et al. "When offered to participate": a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. *J Natl Cancer Inst.* 2021;113(3):244–257.
- U.S. Food and Drug Administration (FDA). FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. Press release April 7, 2021. FDA website. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer>. Accessed June 2023.
- U.S. National Library of Medicine. ClinicalTrials.gov. ClinicalTrials.gov website. <https://clinicaltrials.gov/>. Accessed June 2023.
- Vidula N, Yau C, Rugo HS. Trop2 gene expression (Trop2e) in primary breast cancer (BC): correlations with clinical and tumor characteristics. *J Clin Oncol.* 2017;35(15_suppl):1075–1075.
- Walker S, Carlson M, White CB, et al. Increasing black patient participation in metastatic breast cancer clinical trials: The BECOME (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement. *J Clin Oncol.* 2022;40(no.16_suppl):1014.
- Wang F, Zheng W, Bailey CE, et al. Racial/ethnic disparities in all-cause mortality among patients diagnosed with triple-negative breast cancer. *Cancer Res.* 2021;81(4):1163–1170.